314 related articles for article (PubMed ID: 24857106)
1. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract][Full Text] [Related]
2. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
4. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
6. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
7. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Tannir N; Hammers H; Amin A
Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
9. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
10. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
11. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
12. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.
Makhov P; Joshi S; Ghatalia P; Kutikov A; Uzzo RG; Kolenko VM
Mol Cancer Ther; 2018 Jul; 17(7):1355-1364. PubMed ID: 29967214
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in kidney cancer: the past, present, and future.
Hammers H
Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
16. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
Cho D; Signoretti S; Regan M; Mier JW; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):758s-763s. PubMed ID: 17255306
[TBL] [Abstract][Full Text] [Related]
17. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
18. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
Calvo E; Porta C; Grünwald V; Escudier B
Oncologist; 2019 Mar; 24(3):338-348. PubMed ID: 30158285
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
